Donor cells battle Post-Transplant cancer in major trial

NCT ID NCT00033475

Summary

This study tested whether adding specially prepared donor white blood cells to a reduction in anti-rejection drugs works better than just reducing the drugs alone. It involved 50 people who developed a type of cancer linked to Epstein-Barr virus after receiving a heart, lung, liver, or kidney transplant. The goal was to see if the donor cells could help control the cancer and improve survival.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LYMPHOPROLIFERATIVE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Birmingham Children's Hospital

    Birmingham, England, B4 6NH, United Kingdom

  • Central Manchester and Manchester Children's University Hospitals NHS Trust

    Manchester, England, M27 4HA, United Kingdom

  • Institute of Cancer Research - UK

    Sutton, England, SM2 5NG, United Kingdom

  • King's College Hospital

    London, England, SE5 8RX, United Kingdom

  • Northern General Hospital

    Sheffield, England, S5 7AU, United Kingdom

  • Papworth Hospital

    Cambridge, England, CB3 8RE, United Kingdom

  • Royal Free and University College Medical School

    London, England, NW3 2PF, United Kingdom

  • Royal Infirmary - Castle

    Glasgow, Scotland, G4 0SF, United Kingdom

  • Royal Infirmary of Edinburgh at Little France

    Edinburgh, Scotland, EH16 4SA, United Kingdom

  • University of Edinburgh

    Edinburgh, Scotland, EH8 1QH, United Kingdom

  • University of Edinburgh Laboratory for Clinical and Molecular Virology

    Edinburgh, Scotland, EH9 1QH, United Kingdom

  • Wythenshawe Hospital

    Manchester, England, M23 9LJ, United Kingdom

Conditions

Explore the condition pages connected to this study.